Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval

Signage is seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Join now for FREE unlimited access to Reuters.com Register Aug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved Bluebird Bio’s (BLUE.O) gene therapy for patients with a rare disease …

Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval Read More »